90/019,502ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF11,365,394Closed

Status

Reexamination Certificate Issued

Filed

May 2, 2024

Last Updated

Oct 15, 2025

Art Unit

3991

Requester

Unknown

Requester Law Firm

Foley Hoag, LLP

Requested By

Third Party

Patent OwnerInferred

Fate Therapeutics Inc.

Sector (CPC)

CChemistry & Materials
C12Biotechnology
C12NMicroorganisms & Enzymes

USPC

424Drug, Bio-Affecting And Body Treating Compositions

Reexam History (40 events)

Oct 15, 2025REEXInput Issue Number and Issue Date for Reexamination
Sep 28, 2025RXPUBSReexam Forwarded to Office of Publications
Aug 25, 2025MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Aug 21, 2025PRXRParalegal Reexam Review Complete
Jul 29, 2025MREXNRX - Mail Examiner Interview Summary Record
Jul 14, 2025RXLET.Miscellaneous Incoming Letter
Jul 14, 2025RXC/SRCertificate of Service
Jul 14, 2025RXAAF.Response to Final Filed (or Ready for Examiner Action)
May 14, 2025MRXFRRX - Mail Final Rejection
May 4, 2025IDSCInformation Disclosure Statement considered
Apr 15, 2025DOCKCase Docketed to Examiner in GAU
Mar 12, 2025WIDSInformation Disclosure Statement (IDS) Filed
Mar 12, 2025RXIDS.Information Disclosure Statement Filed
Mar 12, 2025RXC/SRCertificate of Service
Mar 12, 2025RXA...Response after Non-Final Action
Mar 12, 2025BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Mar 7, 2025MREXNRX - Mail Examiner Interview Summary Record
Feb 19, 2025RXLET.Miscellaneous Incoming Letter
Jan 14, 2025MR.NFRX - Mail Reexam Non-Final Action
Aug 27, 2024RXFWDXDate Forwarded to Examiner
Jun 21, 2024MREXORX - Mail Ex Parte Request for Reexamination Granted
May 14, 2024MRPWPRX - Mail Pilot Waiver Program - Ex Parte Interview Summary
May 13, 2024DOCKCase Docketed to Examiner in GAU
May 9, 2024RXTTLRPTTitle Report
May 7, 2024MRXNReexamination Formalities Notice Mailed
May 7, 2024MRXNReexamination Formalities Notice Mailed
May 7, 2024COMPApplication Is Now Complete
May 6, 2024SMALApplicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27
May 6, 2024RXPCOMCompletion of Preprocessing - Released to Assigned GAU
May 3, 2024RXNREQAUNotice of assignment of reexamination request
May 2, 2024WIDSInformation Disclosure Statement (IDS) Filed
May 2, 2024RXRLFReExam Litigation Found
May 2, 2024RXOSUB.RReexamination requested by third party requester
May 2, 2024RXOSUBReceipt of Original Ex Parte Reexam Request
May 2, 2024RXNREQFDNotice of reexamination request filing date
May 2, 2024RXIDS.RReexam - Information Disclosure Statement Filed by Third Party Requester
May 2, 2024RXC/SRCertificate of Service
May 2, 2024PRXRParalegal Reexam Review Complete
May 2, 2024FTFSFITF set to YES - revise initial setting
May 2, 2024BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

Filed — ApprovedOct 6, 2021

Prosecution History

DateCodeDescription
Oct 6, 2021P574PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED
Oct 6, 2021DISTTerminal Disclaimer Filed

Maintenance Fees

Grant
Jun 21, 2022
3.5-yr
Dec 21, 2025
Paid Dec 22, 2025
7.5-yr
Dec 21, 2029
11.5-yr
Dec 21, 2033
Expiry
Feb 19, 2041

Entity Status

Large Entity

Expires

Feb 19, 2041 (14.9 yr remaining)

Assignments

Apr 2019May 2019Jun 2019Jul 2019Aug 2019Sep 2019Oct 2019Nov 2019Dec 2019Jan 2020Feb 2020Mar 2020Apr 2020May 2020Jun 2020Jul 2020Aug 2020Sep 2020Oct 2020Nov 2020Dec 2020Jan 2021Feb 2021FiledRYAN BJORDAHLJODE GOODRIDGETOM TONG LEEBAHRAM VALAMEHRFATE THERAPEUTICS, INC.
AssignmentReel/Frame: 055357/0099Recorded: Feb 22, 2021

From

RYAN BJORDAHLInventor
Mar 28, 2019
JODE GOODRIDGEInventor
Mar 28, 2019
TOM TONG LEEInventor
Mar 28, 2019
BAHRAM VALAMEHRInventor
Mar 28, 2019

To

FATE THERAPEUTICS, INC.